Claims
- 1. A compound of formula i:
- 2. The compound of claim 1, wherein R1=and R2=.
- 3. The compound of claim 1, wherein R1=and R2=.
- 4. The compound of claim 1, wherein R1=and R2=.
- 5. The compound of claim 1, wherein R1=and R2=.
- 6. 6,6,10,11-tetramethyl-4-propyl-2H,6H,12H-benzo[1,2-b:3,4-b′:5,6- b″]tripyran-2,12-dione.
- 7. A compound of formula ii:
- 8. The compound of claim 7, wherein R1=H and R2=R3=CH3.
- 9. The compound of claim 7, wherein R1=R2=R3=H.
- 10. The compound of claim 7, wherein R1=R2CH3 and R3=H.
- 11. A compound of formula iii:
- 12. The compound of claim 11, wherein R1=ethyl.
- 13. The compound of claim 11, wherein R1=isopropyl.
- 14. The compound of claim 11, having formula vi:
- 15. The compound of claim 14, wherein R1=ethyl.
- 16. The compound of claim 14, wherein R1=isopropyl.
- 17. A compound of formula iv:
- 18. The compound of claim 17, wherein R1=propyl and R2=OH.
- 19. The compound of claim 17, wherein R1=phenyl and R2=OH.
- 20. The compound of claim 17, wherein R1=propyl and R2=OH.
- 21. The compound of claim 17, having formula vii:
- 22. The compound of claim 21, wherein R1=propyl and R2=OH.
- 23. The compound of claim 21, wherein R1=phenyl and R2=OH.
- 24. The compound of claim 21, wherein R1=propyl and R2=OH.
- 25. A method of preventing or treating a viral infection comprising administering to a mammal an effective, non-toxic amount of at least one antiviral compound of the formula I:
- 26. The method of claim 25, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 27. The method of claim 26, wherein the herpes virus is Herpes Simplex Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 28. The method of claim 26, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, or Respiratory Syncytial Virus.
- 29. The method of claim 25, wherein the antiviral compound comprises formula i:
- 30. The method of claim 29, wherein R1=and R2=.
- 31. The method of claim 29, wherein R1=and R2=.
- 32. The method of claim 29, wherein R1=and R2=.
- 33. The method of claim 29, wherein R1=and R2=.
- 34. The method of claim 29, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 35. The method of claim 34, wherein the herpes virus is Herpes Simplex Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 36. The method of claim 34, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, or Respiratory Syncytial Virus.
- 37. The method of claim 30, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, Cytomegalovirus, Epstein Barr Virus, or measles.
- 38. The method of claim 25, wherein the antiviral compound comprises 6,6,10,11 -tetramethyl-4-propyl-2H,6H, 12H-benzo[1,2-b:3,4-b′:5,6-b″]tripyran-2,12-dione.
- 39. The method of claim 38, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 40. The method of claim 39, wherein the herpes virus is Herpes Simplex Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 41. The method of claim 39, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, or Respiratory Syncytial Virus.
- 42. The method of claim 25, wherein the antiviral compound comprises formula ii:
- 43. The method of claim 42, wherein R1=H and R2=R3=CH3.
- 44. The method of claim 42, wherein R1=R2=R3=H.
- 45. The method of claim 42, wherein R1=R2=CH3 and R3=H.
- 46. The method of claim 42, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 47. The method of claim 46, wherein the herpes virus is Herpes Simplex Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 48. The method of claim 46, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, or Respiratory Syncytial Virus.
- 49. The method of claim 44, wherein the viral infection is from Hepatitis B.
- 50. The method of claim 45, wherein the viral infection is from Hepatitis B.
- 51. The method of claim 25, wherein the antiviral compound comprises formula iii:
- 52. The method of claim 51, wherein R1=ethyl.
- 53. The method of claim 51, wherein R1=isopropyl.
- 54. The method of claim 51, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 55. The method of claim 54, wherein the herpes virus is Herpes Simplex Type l, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 56. The method of claim 54, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, and Respiratory Syncytial Virus.
- 57. The method of claim 51, wherein the antiviral compound comprises formula vi:
- 58. The method of claim 57, wherein R1=ethyl.
- 59. The method of claim 57, wherein R1=isopropyl.
- 60. The method of claim 57, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 61. The method of claim 60, wherein the herpes virus is Herpes Simplex Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 62. The method of claim 60, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, and Respiratory Syncytial Virus.
- 63. The method of claim 25, wherein the antiviral compound comprises formula iv:
- 64. The method of claim 63, wherein R1=propyl and R2=OH.
- 65. The method of claim 63, wherein R1=phenyl and R2=OH.
- 66. The method of claim 63, wherein R1=propyl and R2=OH.
- 67. The method of claim 63, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 68. The method of claim 67, wherein the herpes virus is Herpes Simplex 1 0 Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 69. The method of claim 67, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, and Respiratory Syncytial Virus.
- 70. The method of claim 64, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B or Cytomegalovirus.
- 71. The method of claim 63, wherein the antiviral compound comprises formula vii:
- 72. The method of claim 71, wherein R1=propyl and R2=OH.
- 73. The method of claim 71, wherein R1=phenyl and R2=OH.
- 74. The method of claim 71, wherein R1=propyl and R2=OH.
- 75. The method of claim 71, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B, a herpes virus, or a respiratory virus.
- 76. The method of claim 75, wherein the herpes virus is Herpes Simplex Type 1, Herpes Simplex Type 2, Cytomegalovirus, Varicella Zoster Virus, or Epstein Barr Virus.
- 77. The method of claim 75, wherein the respiratory virus is Influenza A, Influenza B, Parainfluenza, Adenovirus, Measles, and Respiratory Syncytial Virus.
- 78. The method of claim 72, wherein the viral infection is from a virus selected from the group consisting of Hepatitis B or Cytomegalovirus.
- 79. The method of claim 25, which further comprises co-administering an effective therapeutic amount of at least one compound selected from the group consisting of a second antiviral compound, an immunostimulant, an immunomodulator, an antibiotic, or a chemokine inhibitor.
- 80. The method of claim 79, wherein the second antiviral compound is a protease inhibitor.
- 81. The method of claim 80, wherein the protease inhibitor is selected from the group consisting of indinavir, saquinavir, ritonavir, and nelfmavir.
- 82. The method of claim 79, wherein the second antiviral compound is a biflavanoid.
- 83. The method of claim 82, wherein the biflavanoid is selected from the group consisting of robustaflavone, amentoflavone, and a derivate or salt thereof.
- 84. The method of claim 79, wherein the second antiviral compound is selected from the group consisting of AZT, ddC, ddI, D4T, 3TC, acyclovir, gancyclovir, fluorinated nucleosides and nonnucleoside analog compounds such as TIBO derivatives and nevirapine, α-interfon, recombinant CD4, amantadine, rimantadine, ribavirin, and vidarabine.
- 85. The method of claim 79, wherein the immunostimulant is an interleukin or cytokine.
- 86. The method of claim 79, wherein the antibiotic is an antibacterial agent, antifungal agent, or anti-pneumocysitis agent.
- 87. A compound of the formula I:
- 88. The compound of claim 87, having formula viii:
- 89. The compound of claim 88 wherein R3is methyl.
- 90. The compound of claim 89 wherein R4is methyl.
- 91. The compound of claim 90 wherein R8 is H.
- 92. The compound of claim 91 wherein R9 is methyl.
- 93. The compound of claim 92 wherein R1 is phenyl.
- 94. The compound of claim 92 wherein R1 is n-propyl.
- 95. The compound of claim 88, wherein R1=n-propyl; R3=R4=R5=R6=R9=methly; R2=R7=R8=H; and R10=OH.
- 96. The compound of claim 88, wherein R1=n-propyl; R3=R4=R5=R6=R8=methyl; R2=R7=R9=H; and R10=OH.
- 97. The compound of claim 89 wherein R4 is H.
- 98. The compound of claim 97 wherein R8 is H.
- 99. The compound of claim 98 wherein R9 is ethyl.
- 100. The compound of claim 99 wherein R1 is phenyl.
- 101. The compound of claim 99 wherein R1 is n-propyl.
- 102. The compound of claim 88, wherein R1=n-propyl; R2=R4=R7 =R8=H; R3=R5=R6=methyl; R10=ethyl; and R10=OH.
- 103. The compound of claim 88, wherein R1=n-propyl; R2=R3=R7=R9=H; R4=R5=R6=methiyl; R8=ethyl; and R10=OH.
- 104. The compound of claim 88, wherein R1=n-propyl, R2=R3=R7=R8=H; R4=R5=R6=methyl; R8=ethyl; and R10=OH.
- 105. The compound of claim 88, wherein R1=n-propyl, R2=R4=R7=R9=H; R3=R5=R6=methyl; R8=ethyl; and R10=OH.
- 106. The compound of claim 89 wherein R8 is methyl.
- 107. The compound of claim 106 wherein R9 is methyl.
- 108. The compound of claim 107 wherein R4 is H.
- 109. The compound of claim 108 wherein R1 is phenyl.
- 110. The compound of claim 108 wherein R1 is n-propyl.
- 111. The compound of claim 108, wherein R1=n-propyl; R2=R4=R7=H; R3=R5=R6=R8=R9=metiyl; and R10=OH.
- 112. The compound of claim 88, wherein R1=n-propyl; R2=R3=R7=H; R4=R5=R6=R8=R9=methyl; and R10=OH.
- 113. The compound of claim 87, having formula ix:
- 114. The compound of claim 87, having formula x:
CROSS-REFERENCE
[0001] This is a continuation-in-part of co-pending U.S. patent application Ser. No. 08/609,537, filed Mar. 1, 1996, which is a continuation-in-part of co-pending U.S. patent application Ser. No. 08/510,213, filed Aug. 2, 1995, which in turn is a continuation-in-part of U.S. patent application Ser. No. 08/285,655, filed Aug. 3, 1994, now U.S. Pat. No. 5,489,697 issued Feb. 6, 1996.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09173143 |
Oct 1998 |
US |
Child |
09814074 |
Mar 2001 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
08609537 |
Mar 1996 |
US |
Child |
09173143 |
Oct 1998 |
US |
Parent |
08510213 |
Aug 1995 |
US |
Child |
08609537 |
Mar 1996 |
US |
Parent |
08285655 |
Aug 1994 |
US |
Child |
08510213 |
Aug 1995 |
US |